Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 41 to 50 of 330

TitleReference numberPublishedLast updated
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal)TA1032
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1030
Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal)TA1024
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA1021
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1017
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancerTA1014
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatmentsTA1008
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancerTA1007
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancerTA737
Relugolix for treating hormone-sensitive prostate cancerTA995

Results per page

  1. 10
  2. 25
  3. 50
  4. All